Please login to the form below

Not currently logged in
Email:
Password:

Excellence in Customer Focus - Physician/Prescribing

Sponsored by

Finalist

A new chapter in Dupuytren's contracture treatment

Pfizer in association with FTI Consulting


Summary of work

An innovative medical education programme helped Pfizer introduce the first pharmaceutical product to a disease area and customer group – comprising physicians treating hand disorders – that was already satisfied with established surgical techniques. 

XIAPEX, an injectable treatment for Dupuytren’s contracture in adult patients with a palpable cord, was launched by Pfizer in Europe in March 2011 as an alternative for patients. Market research shows many patients refer to surgery as a “last resort”.  

In a risk-averse regulatory environment, Pfizer recognised the need to develop a formal training programme, as the treatment procedure is unlike surgical intervention and the injection must be precise to protect patients by avoiding serious adverse events. 

The core training programme, including a detailed brochure, video and online course, was developed with Europe’s foremost hand specialists and helped secure marketing authorisation in February 2011. The programme was disseminated via a peer-to-peer education cascade, involving training workshops, symposia and development of a bespoke training model. 

Knowledge of XIAPEX and interest in introducing it into clinical practice have increased dramatically, with over 2,000 hand, orthopaedic and plastic surgeons in 13 countries trained how to use XIAPEX in 2011 alone. Customer feedback on the training programme has been consistently excellent.

 

 

Executive summary as submitted


COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Impetus Digital

Impetus Digital has offered virtual advisory boards, clinical trial investigator consortiums, co-author publication working groups, steering committees, and medical education...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
PME-MAY21-Cover
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....